ClinicalTrials.gg
TerminatedNCT04798989Updated Oct 30, 2024Results posted

A Study of the Effects of CY6463 in Participants With Alzheimer's Disease With Vascular Pathology

A Phase 2 interventional study of CY6463 and Placebo in Alzheimer's Disease With Vascular Pathology, sponsored by Tisento Therapeutics. Terminated at 5 sites in United States. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2024-10-30.

Sponsored by Tisento Therapeutics · Phase 2, Interventional, and Treatment

Why this study was terminated
Due to enrollment challenges

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,940 studies in Alzheimer Disease with a site in United States — 346 open to participants now, 445 under way, 40 of them phase 3. Alzheimer Disease · United States.

Enrollment
1,419th of 1,609
12 · median 73
Started
2021
with 144 others
Phase 2
360 of 1,940
50 open now
Registered
1,308th of 1,940
by date

Among the 1,940 studies in Alzheimer Disease with a site in United States, this one is the 1,419th largest by enrollment of the 1,609 interventional ones that give a count, is one of 145 that started in 2021, is one of 360 in phase 2, and was the 1,308th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

346 of the 1,940 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,940 studies in Alzheimer Disease with a site in United States, or all of them as a file.
02

Study summary

This study is being conducted to test the safety, tolerability, and pharmacokinetics of the investigational drug CY6463 compared with placebo in individuals who are aged 60 years or older and have Alzheimer's disease (AD) along with common cardiovascular risk factors.

Read the detailed description

CY6463 is an investigational drug being developed as a symptomatic and potentially disease-modifying therapy for Alzheimer's disease (AD) and other serious central nervous system disorders. As a soluble guanylate cyclase (sGC) stimulator, CY6463 can cross the blood-brain barrier and boosts the activity of the nitric oxide-soluble guanylate cyclase-cyclic guanosine monophosphate (NO-sGC-cGMP) pathway. This signaling pathway is important in many aspects of brain health, including in the control of blood flow in the brain, how brain cells use energy, and how those cells communicate with one another. Impairment of this pathway is a critical part of the origin of many neurodegenerative diseases that can cause a loss of brain function including memory and decision-making abilities. There are clear links between disrupted NO signaling and impaired brain function in patients with AD and vascular pathology (ADv). ("Vascular pathology" refers to abnormalities of the blood vessels that are more likely to occur when a person has cardiovascular risk factors like high blood pressure, diabetes, and/or obesity.) It is hypothesized that CY6463 may help patients with ADv maintain or recover some of their original cognitive function.

In this study, participants will be randomized to receive approximately 87 sequential days (\~3 months) of study drug (CY6463 or placebo) once daily (QD) and will complete 7 scheduled site visits over the course of the study, from Screening through Follow up.

03

Conditions studied

  • Alzheimer's Disease With Vascular Pathology

Keywords

  • Alzheimer's disease
  • AD
  • ADv
  • CY6463
  • Subcortical small-vessel disease
  • Elderly
  • 60 and older
  • Probable AD dementia
  • Vascular dementia
  • Mixed dementia
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provide written prior to the performance of any protocol-specified procedure or, if unable to provide informed consent due to cognitive status, provides assent to participate, with a legally authorized representative (LAR) providing written informed consent on behalf of the participant.
  2. 60 years of age or older
  3. Meets core clinical criteria for probable AD dementia according to the 2011 National Institute on Aging-Alzheimer's Associated guidelines. Can be based on medical history.
  4. (MMSE) score of 20 to 26 (inclusive)
  5. Confirmation of AD pathophysiology
  6. At least 2 cardiovascular risk factors per protocol criteria
  7. Magnetic resonance imaging (MRI) scan (existing MRI obtained ≤6 months before Screening is acceptable) findings of mild-to-moderate subcortical small-vessel disease
  8. If receiving concomitant or chronic medication(s), has had no change for ≥4 weeks before study drug initiation and has no plans to alter the regimen(s) during the study
  9. If male, agrees to refrain from donating sperm from the Screening visit through 90 days after taking the final study drug dose
  10. If male, agrees to use protocol-specified, effective methods from the signing of the informed consent form (ICF) until ≥90 days after taking the final study drug dose.
  11. If female, is /not of defined per protocol
  12. Agrees to the study procedures, including undergoing lumbar puncture for cerebrospinal fluid (CSF) samples

Exclusion criteria

Exclusion Criteria:

  1. Severe visual, auditory, social, or cognitive impairment
  2. Dementia-related disorder other than AD or vascular dementia (eg, Parkinson's disease, Huntington's disease, frontotemporal dementia, schizophrenia, Lewy body dementia)
  3. Symptomatic large-vessel disease, symptomatic carotid artery disease, large vessel infarcts, or strategic lacunar infarcts or infarcts>15 mm
  4. History of significant central nervous system (CNS) trauma that has affected brain function
  5. Low blood pressure (BP), defined as systolic BP ≤90 mmHg or diastolic BP ≤60 mmHg.
  6. Orthostatic hypotension.
  7. Unable to undergo MRI
  8. Unable to undergo lumbar puncture procedure
  9. Unable to participate in electroencephalography (EEG) protocol due to hearing impairment or inability to tolerate EEG cap or headphones
  10. Uncontrolled or unstable chronic disease
  11. Kidney impairment requiring dialysis; history of renal transplant
  12. Needs continuous direct medical care and nursing supervision.
  13. Family history of short syndrome or long QT syndrome
  14. cardiac involvement
  15. History of cancer. Exceptions: localized cutaneous basal or squamous cell carcinoma in the last 5 years, low-grade localized prostate/cervical cancers, or previous localized prostate/cervical cancers that have a low likelihood of recurrence
  16. Is not suited for study participation in the clinical judgment of the investigator

Additional inclusion and exclusion criteria apply, per protocol.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    CY6463

    CY6463 once daily (QD) for approximately 87 sequential days.

    Drug: CY6463

  • Placebo comparator
    Placebo

    Placebo QD for approximately 87 sequential days.

    Drug: Placebo

Interventions

  • DrugCY6463

    CY6463 Oral Tablet

    Also known as: IW-6463, zagociguat

  • DrugPlacebo

    Placebo Oral Tablet

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-emergent Adverse Events (TEAEs) From Study Drug Initiation Through Follow-up

    TEAE is defined as an adverse event with an onset that occurs after receiving the study drug, until the end of the Follow-up period

    Time frame: From first dose of study treatment through ~14 (±4) days after the final dose

07

Results

Posted Oct 30, 2024

Participant flow

Participant flow — Overall Study
MilestonePlaceboCY6463
Started66
Completed66
Not completed00

Outcome measures

PrimaryIncidence of Treatment-emergent Adverse Events (TEAEs) From Study Drug Initiation Through Follow-up

TEAE is defined as an adverse event with an onset that occurs after receiving the study drug, until the end of the Follow-up period

Time frame:
From first dose of study treatment through ~14 (±4) days after the final dose
Reported as:
Count of participants · Participants
Incidence of Treatment-emergent Adverse Events (TEAEs) From Study Drug Initiation Through Follow-up
ParticipantsPlaceboCY6463
Incidence of Treatment-emergent Adverse Events (TEAEs) From Study Drug Initiation Through Follow-up02

Adverse events

Collected over From informed consent through ~14 (±4) days after the final dose. (Dosing ranged from 84 to 90 days for placebo and 85 to 91 days for CY6463).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/6 (0%)0/6 (0%)0/6 (0%)
CY64630/6 (0%)0/6 (0%)2/6 (33.3%)
Most frequent other events
Most frequent other events
EventPlaceboCY6463
HeadacheNervous system disorders0/62/6
DiarrhoeaGastrointestinal disorders0/61/6
Upper respiratory tract infectionInfections and infestations0/61/6

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)PlaceboCY6463Total
<=18 years000
Between 18 and 65 years101
>=65 years5611
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboCY6463Total
Female123
Male549
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboCY6463Total
Hispanic or Latino235
Not Hispanic or Latino437
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboCY6463Total
Asian123
White347
Black or African American202
08

Study locations

5 sites
  • Clinical Endpoints
    Scottsdale, Arizona 85258, United States
  • Optimus U Corp
    Miami, Florida 33125, United States
  • Hawaii Pacific Neurosciences, LLC
    Honolulu, Hawaii 96817, United States
  • University of Kentucky
    Lexington, Kentucky 40536, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2021 to primary completion in Nov 2022, 12 months.

Results were first posted in Oct 2024, 1 year 11 months after primary completion. A results delay was requested in Oct 2023.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2021
First posted
Mar 16, 2021
StartActual
Nov 2, 2021
Primary completionActual
Nov 28, 2022
CompletionActual
Nov 28, 2022
Results delay requested
Oct 17, 2023
Results first posted
Oct 30, 2024
Last update
Oct 30, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04798989
Lead sponsor
Tisento Therapeutics
Responsible party
Sponsor
First posted
Mar 16, 2021
Start date
Nov 2, 2021
Primary completion
Nov 28, 2022
Completion
Nov 28, 2022
Results posted
Oct 30, 2024
Last update
Oct 30, 2024

Study contacts

Study Director
study director · Tisento Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zagociguat

Start the discussion